NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
Country Total

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 1757 1.1% 661 0.4% 259 0.2% 11 0.0% 10 0.0% 82 0.1% 150658 98.2% 153438 100.0%
ASCUS 4165 24.3% 3642 21.2% 1707 9.9% 48 0.3% 24 0.1% 256 1.5% 7322 42.7% 17164 100.0%
LSIL 1670 20.0% 2501 30.0% 1449 17.4% 12 0.1% 11 0.1% 138 1.7% 2552 30.6% 8333 100.0%
Atypical glandular cells/AGC 84 25.0% 53 15.8% 81 24.1% 59 17.6% 27 8.0% 8 2.4% 24 7.1% 336 100.0%
Unclear atypia 35 26.5% 20 15.2% 50 37.9% 6 4.5% 6 4.5% 4 3.0% 11 8.3% 132 100.0%
ASC-H 204 14.1% 255 17.6% 862 59.7% 16 1.1% 26 1.8% 9 0.6% 73 5.1% 1445 100.0%
HSIL 113 5.6% 207 10.3% 1471 73.0% 36 1.8% 62 3.1% 11 0.5% 115 5.7% 2015 100.0%
Suspected Adenocarcinom 2 3.4% 4 6.9% 5 8.6% 25 43.1% 13 22.4% . . 9 15.5% 58 100.0%
Malignant tumor with unclear origin . . . . 1 100.0% . . . . . . . . 1 100.0%
Squamous cell cancer . . . . 10 58.8% . . 6 35.3% . . 1 5.9% 17 100.0%
Totalt 8030 4.4% 7343 4.0% 5895 3.2% 213 0.1% 185 0.1% 508 0.3% 160765 87.9% 182939 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M69760, M80009, M80413, M80703, M80706, M81403, M82003, M85603